Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
Ist Teil von
British journal of cancer, 2014-12, Vol.111 (12), p.2254-2261
Ort / Verlag
London: Nature Publishing Group UK
Erscheinungsjahr
2014
Quelle
Free E-Journal (出版社公開部分のみ)
Beschreibungen/Notizen
Background:
Preoperative radiotherapy (RT) is commonly used to treat localised soft-tissue sarcomas (STS). Hypoxia is an important determinant of radioresistance. Whether antiangiogenic therapy can ‘normalise’ tumour vasculature, thereby improving oxygenation, remains unknown.
Methods:
Two cohorts were prospectively enrolled. Cohort A evaluated the implications of hypoxia in STS, using the hypoxic tracer
18
F-azomycin arabinoside (FAZA-PET). In cohort B, sunitinib was added to preoperative RT in a dose-finding phase 1b/2 design.
Results:
In cohort A, 13 out of 23 tumours were hypoxic (FAZA-PET), correlating with metabolic activity (
r
2
=0.85;
P
<0.001). Two-year progression-free (PFS) and overall (OS) survival were 61% (95% CI: 0.44–0.84) and 87% (95% CI: 0.74–1.00), respectively. Hypoxia was associated with radioresistance (
P
=0.012), higher local recurrence (Hazard ratio (HR): 10.2;
P
=0.02), PFS (HR: 8.4;
P
=0.02), and OS (HR: 41.4;
P
<0.04). In Cohort B, seven patients received sunitinib at dose level (DL): 0 (50 mg per day for 2 weeks before RT; 25 mg per day during RT) and two patients received DL: −1 (37.5 mg per day for entire period). Dose-limiting toxicities were observed in 4 out of 7 patients at DL 0 and 2 out of 2 patients at DL −1, resulting in premature study closure. Although there was no difference in PFS or OS, patients receiving sunitinib had higher local failure (HR: 8.1;
P
=0.004).
Conclusion:
In STS, hypoxia is associated with adverse outcomes. The combination of sunitinib with preoperative RT resulted in unacceptable toxicities, and higher local relapse rates.